Disclaimer Regarding Forward – Looking StatementsNone of this should be construed as an offer or a solicitation of an offer to buy or sell securities are. This press release contains forward-looking statements based on current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations in the forward looking statements and the assumptions statements, which involveich they are based are reasonable, it that such expectations that such expectations and assumptions have proved to be correct cialis . Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally characterized by the use of the words ‘may,”should,”could,”expect,”anticipate, ”estimate, ‘believe ‘,’intend ‘or’project ‘or the negative of these words or other variations on these words or comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, as these statements are numerous factors and uncertainties, including but not restricted to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and limited products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company’s products, technical problems with the Company’s research and products, price increases for supplies and components, litigation and administrative proceedings with the Company, the possible acquisition of new businesses or technologies that are in operating losses or that do not work as expected, unanticipated losses, the possible fluctuation and volatility of the results of operations, financial condition and stock price, in in litigation and settling cases, the company diluting the ownership of its business, adverse publicity and news coverage, inability to carry out research-, development and commercialization plans, loss or retirement of key executives and scientists, changes in interest rates, inflationary factors and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. U.S. Securities in this release concerning our going research and development and the results attained by us are included to date evaluated by the Food evaluated by the Food and Drug Administration. Further research and development assurance that further research and development, and / or whether clinical trial results, if any , validate and support the results of our preliminary research and studies to be. Furthermore, there is no guarantee that the necessary regulatory approvals will be obtained or that Phytomedical to develop marketable products based on its technologies. In addition, other factors that may cause differ materially differ materially in society most recent Form 10-QSB and Form 10-KSB are discussed with the Securities and Exchange Commission. These reports and filings may be inspected and the Public Reference Room of the U.S. Securities & Exchange Commission at 100 F Street, Washington, DC copies cared 20549th made in order tobtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800 – SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information other other information about issuers that file electronically with the U.S.
Co Dr. Dr. Shenhong Wu, also of Stony Brook University, the results should not cancer patients with Avastin off but the doctors and patients should be more vigilant about signs of clots . Continue reading